What Capmatinib does

The active substance capmatinib in Capmatinib (Capmatinib) is a receptor tyrosine kinase inhibitor that inhibits the phosphorylation of c-Met wild-type and mutant variants triggered by the binding of its endogenous ligand hepatocyte growth factor, thereby preventing c-Met-mediated phosphorylation of downstream signaling proteins, as well as the proliferation and survival of c-Met-dependent tumor cells. Aberrant activation of c-Met has been documented in many cancers, including cancer (NSCLC), where mutations leading to skipping of Met exon 14 lead to the formation of mutant c-Met with missing regulatory domains - these mutant proteins have a reduced negative regulatory capacity, leading to a pathological increase in their downstream activity.